Literature DB >> 15726219

Herbal treatment for renal diseases.

A Peng1, Y Gu, S Y Lin.   

Abstract

Renal fibrosis is a common consequence of chronic kidney diseases (CKD). Standard therapy to prevent progression of CKD in western medicine includes dietary protein restriction, blood pressure control, angiotensin-converting enzyme inhibition and angiotensin receptor blockade. However, little is known about the renoprotective effects of Chinese herbal medicine. Cumulative evidence suggests that some Chinese herbal medicines, including Astragalus and a mixture of Astragalus plus Angelica, Ligusticum, Triptolide and Rhubarb, have a beneficial role in slowing the progression of CKD. This effect is multi-functional and multi-targeted, and is often associated with a reduction in proteinuria and the amelioration of dyslipidaemia, but not with changes in systemic blood pressure. These mechanisms include anti-inflammation and inhibition of TGF-b overproduction. On the other hand, some Chinese herbal medicines may be hazardous to patients with renal diseases. In this review, we discuss recent advances in the research of some Chinese herbs for pharmacological intervention of progressive renal diseases and kidney-related injuries.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726219

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  27 in total

Review 1.  Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae).

Authors:  Anita M Brinker; Jun Ma; Peter E Lipsky; Ilya Raskin
Journal:  Phytochemistry       Date:  2007-01-23       Impact factor: 4.072

2.  Evaluation of the hepatroprotective and nephroprotective activities of Scrophularia hypericifolia growing in Saudi Arabia.

Authors:  Saleh I Alqasoumi
Journal:  Saudi Pharm J       Date:  2013-12-12       Impact factor: 4.330

3.  Nephroprotective drugs from traditionally used Aboriginal medicinal plants.

Authors:  Muhammad N Ghayur; Luke J Janssen
Journal:  Kidney Int       Date:  2010-03       Impact factor: 10.612

4.  Inhibition of adriamycin-induced nephropathy in rats by herbs based kangshenoral solution.

Authors:  Jingsheng Zhao; Xinwei Lin; Xueqing Xiao; Jun Yang; Hong Liu; Weiguo Yi; Zhengchen Zhang; Xinkuan Zhang
Journal:  Int J Clin Exp Med       Date:  2015-12-15

5.  Impairment of triptolide on liver mitochondria in isolated liver mitochondria and HL7702 cell line.

Authors:  Qiang Fu; Zhen-zhou Jiang; Lu-yong Zhang
Journal:  Chin J Integr Med       Date:  2013-04-10       Impact factor: 1.978

Review 6.  Hypoxia: The Force that Drives Chronic Kidney Disease.

Authors:  Qiangwei Fu; Sean P Colgan; Carl Simon Shelley
Journal:  Clin Med Res       Date:  2016-02-04

7.  Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy.

Authors:  L Q Meng; J W Tang; Y Wang; J R Zhao; M Y Shang; M Zhang; S Y Liu; L Qu; S Q Cai; X M Li
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

8.  Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease.

Authors:  Wei Mao; Lei Zhang; Chuan Zou; Chuang Li; Yifan Wu; Guobin Su; Xinfeng Guo; Yuchi Wu; Fuhua Lu; Qizhan Lin; Lixin Wang; Kun Bao; Peng Xu; Daixin Zhao; Yu Peng; Hui Liang; Zhaoyu Lu; Yanxiang Gao; Xina Jie; La Zhang; Zehuai Wen; Xusheng Liu
Journal:  BMC Complement Altern Med       Date:  2015-09-08       Impact factor: 3.659

9.  Acute kidney injury after ingestion of rhubarb: secondary oxalate nephropathy in a patient with type 1 diabetes.

Authors:  Marc Albersmeyer; Robert Hilge; Angelika Schröttle; Max Weiss; Thomas Sitter; Volker Vielhauer
Journal:  BMC Nephrol       Date:  2012-10-30       Impact factor: 2.388

10.  Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen capsule).

Authors:  Jingai Fang; Hongkun Wei; Yanyan Sun; Xiaodong Zhang; Wenyuan Liu; Qintao Chang; Ruihua Wang; Yuewen Gong
Journal:  BMC Complement Altern Med       Date:  2013-04-05       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.